Zevra Therapeutics Posts Strong 2025 Growth on MIPLYFFA Momentum
Event summary
- Zevra Therapeutics reported $106.5M in net revenue for 2025, up from $23.6M in 2024, driven by MIPLYFFA® growth.
- MIPLYFFA® generated $87.4M in net revenue in 2025, with 52 prescriptions in Q4 2025 and 161 since launch.
- Net income for 2025 was $83.2M, a significant turnaround from a $105.5M net loss in 2024.
- The company relocated its global headquarters to Boston to access specialized talent.
- Zevra enrolled 52 patients in the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome by year-end 2025.
The big picture
Zevra Therapeutics' strong 2025 financial performance underscores the accelerating adoption of MIPLYFFA® in the rare disease space. The company's strategic relocation to Boston and ongoing regulatory reviews position it for further growth, though execution risks remain in its clinical pipeline. The shift from net loss to profitability highlights its commercialization success, but sustaining this momentum will depend on regulatory approvals and pipeline advancements.
What we're watching
- Regulatory Progress
- Whether the EMA's review of MIPLYFFA® for Niemann-Pick disease type C will advance as expected, given the 120-day list of questions issued.
- Pipeline Execution
- The pace at which Zevra can enroll patients and achieve milestones in the DiSCOVER trial for Vascular Ehlers-Danlos Syndrome.
- Commercial Expansion
- How Zevra's relocation to Boston and strategic priorities will impact its ability to scale MIPLYFFA® and other products globally.
Related topics